

## Special Issue

# Advances in Immunotherapy for Non-Small-Cell Lung Cancer

### Message from the Guest Editor

Lung cancer is the leading cause of cancer-related death worldwide, with non-small-cell lung cancer being the primary type. The discovery of immune checkpoints and subsequent development of Nobel Prize-winning immune checkpoint inhibitors (ICIs) have brought in a radical revolution in the therapeutic landscape of lung cancer, specifically NSCLC. The landscape of immunotherapy in lung cancer is rapidly expanding, and ICIs have become the standard-of-care treatment for patients with metastatic, locally advanced, and resectable NSCLC, with remarkable improvement in overall survival. In this Special Issue, we invite investigators to contribute original research or review articles that highlight recent important advances in immunotherapy for NSCLC. Potential topics include, but are not limited to, the following:

- Genomic and proteomic characteristics of NSCLC and immunotherapy;
- Tumor microenvironment and immunotherapy of NSCLC;
- Single/combination immunotherapy in NSCLC;
- Side effects of immunotherapy in NSCLC.

### Guest Editor

Dr. Raheleh Roudi

Molecular Imaging Program at Stanford, Department of Radiology,  
Stanford University, Stanford, CA 94305, USA

### Deadline for manuscript submissions

20 September 2025



## Cells

an Open Access Journal  
by MDPI

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/si/212576](https://mdpi.com/si/212576)

*Cells*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cells@mdpi.com](mailto:cells@mdpi.com)

[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)





# Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)



## About the Journal

### Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

---

### Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,  
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,  
Copenhagen, Denmark

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).